Objective: Cough caused by angiotensin-converting enzyme inhibitors (ACEIs) limits their clinical application and cardiovascular benefits. This randomized trial investigated whether genotype-guided perindopril use could reduce drug-related cough in 20 to 79-year-old individuals with hypertension.
Methods: After screening 120 patients and randomization, 68 were assigned to genotyping ( n = 41) and control ( n = 27) groups. NELL1 p.Arg382Trp (rs8176786) and intron (rs10766756) genotype information was used to subdivide the genotyping group into high-risk and low-risk subgroups with at least one or no risk alleles for ACEI-related cough, respectively. The high-risk subgroup received candesartan (8 mg/day) for 6 weeks, whereas the low-risk subgroup received perindopril (4 mg/day). The control group, which was not genotyped, received perindopril (4 mg/day). The primary outcome variables were cough and moderate/severe cough; the secondary outcome variable was any adverse event.
Results: During the 6-week period, the risk of cough was lower in the genotyping group than in the control group [five (12.2%) and nine (33.3%) participants, respectively; hazard ratio: 0.25; log-rank P = 0.017]. The moderate/severe cough risk was also lower in the genotyping group [one (2.4%) and five (18.5%) participants, respectively; hazard ratio: 0.12; log-rank P = 0.025]. Differences in cough (hazard ratio: 0.56; log-rank P = 0.32) and moderate/severe cough risk (hazard ratio: 0.26; log-rank P = 0.19) between the low-risk and control groups were not significant. The risk of total adverse events was similar between any two groups.
Conclusion: Cough risk was lower during genotype-guided treatment than during conventional treatment. These results support the utility of NELL1 variant data in clinical decision making to personalize renin-angiotensin system blocker therapy use.
Trial Registration: ClinicalTrials.gov number: NCT05535595 (retrospectively registered at September 7, 2022).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HJH.0000000000003536 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical stage-specific prognostic impact of adequate lymphadenectomy in early-stage lung cancer.
Eur J Cardiothorac Surg
March 2025
Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, ; Taipei City, Taiwan.
Objectives: To assess the prognostic impact of adequate lymphadenectomy and determine the optimal nodal assessment for different clinical stages of lung cancer.
Methods: We retrospectively reviewed 1214 patients with clinical stage I-III non-small cell lung cancer who had preoperative PET/CT and curative surgery (2006-2017). Patients were categorized based on whether they had adequate [R0] or inadequate lymphadenectomy [R(un)].
Ocular motor cranial neuropathy and risk of thyroid cancer: A Korean population-based study.
PLoS One
March 2025
Department of Ophthalmology, Hallym University School of Medicine, Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea.
This study investigates whether ocular motor cranial neuropathy (OMCN) can predict the onset of thyroid cancer given its association with common cardiovascular risk factors including obesity, diabetes mellitus (DM), hypertension, and dyslipidemia. We conducted a retrospective, nationwide, population-based cohort study utilizing data from the Korean National Health Insurance Service. Individuals comprised those aged ≥ 20 years diagnosed with OMCN between 2010 and 2017.
View Article and Find Full Text PDFMoney Matters: The Effect of Income on Postsurgical Outcomes in Stage IA Non-small Cell Lung Cancer.
Ann Surg Oncol
March 2025
Department of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ, USA.
Background: Treatment of non-small cell lung cancer (NSCLC) remains challenging; 5-year survival is as low as 24% for resectable disease. However, the outlook for stage IA NSCLC is favorable, with 5-year survival exceeding 74% and with surgery often being curative. Despite this positive prognosis, low socioeconomic status has been shown to correlate with nonstandard treatment and worse overall survival specifically in stage IA.
View Article and Find Full Text PDFHepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching.
Radiol Med
March 2025
Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Dongfeng East Road 651, Guangzhou, 510260, Guangdong Province, China.
Purpose: Hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib (Len) and immune checkpoint inhibitor (ICI) in treating advanced hepatocellular carcinoma (HCC) still needs further confirmation. We aimed to evaluate the efficacy of HAIC combined with Len and ICI (HAIC + Len + ICI) versus Len alone in advanced HCC.
Methods: A total of 290 patients in Len group and 349 patients in HAIC + Len + ICI group were analysed.
Inadequate sleep increases stroke risk: evidence from a comprehensive meta-analysis of incidence and mortality.
Geroscience
March 2025
Dept. Of Bioinformatics, Semmelweis University, 1094, Budapest, Hungary.
The link between abnormal sleep duration and stroke outcomes remains contentious. This meta-analysis quantifies how both short and long sleep durations impact stroke incidence and mortality. A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, Embase, and Google Scholar up to November 1, 2024, to identify cohort studies evaluating sleep duration and stroke outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!